Active Trials
15
Total Enrollment
11.1K
Market Opportunity
$75.4B
Avg Retention
91%
Top Therapeutic Area
Oncology
Clinical Trials by Phase
Therapeutic Area Distribution
Upcoming Clinical Trials to Watch
15 trialsNCT05187578Phase 2Oncology
Cytiva Therapeutics
Novel CAR-T Therapy for Relapsed B-Cell Lymphoma
CTX-451B-Cell Lymphoma4 countries142/200 enrolled
$2.8B
Market Opportunity
NCT04983272Phase 3Metabolic
Metabolic Sciences Inc
Oral GLP-1 Agonist for Type 2 Diabetes
GLP-5701Type 2 Diabetes5 countries1847/2000 enrolled
$15.0B
Market Opportunity
NCT05042162Phase 1/2Rare Disease
GenCure Biologics
Gene Therapy for Duchenne Muscular Dystrophy
GT-DMD-01Duchenne Muscular Dystrophy3 countries18/36 enrolled
$1.2B
Market Opportunity
NCT04872693Phase 3Neuroscience
NeuroShine Pharma
Anti-Tau Antibody for Early Alzheimer's Disease
TAU-998Alzheimer's Disease5 countries1563/1800 enrolled
$13.0B
Market Opportunity
NCT05284714Phase 2Oncology
OncoTarget Therapeutics
KRAS G12C Inhibitor for Pancreatic Cancer
KRA-2024Pancreatic Cancer4 countries89/120 enrolled
$850.0M
Market Opportunity
NCT05129478Phase 1/2Gene Editing
EditGen Therapeutics
CRISPR-Based Sickle Cell Cure
CRISPR-SC-001Sickle Cell Disease4 countries24/45 enrolled
$2.1B
Market Opportunity
NCT05657891Phase 3Oncology
ImmunoCore Bio
Bispecific Antibody for Non-Small Cell Lung Cancer
IMC-LUNG-2024Non-Small Cell Lung Cancer5 countries892/1200 enrolled
$5.8B
Market Opportunity
NCT05589234Phase 3Infectious Disease
Moderna
RNA-Based Vaccine for Respiratory Syncytial Virus
mRNA-1345RSV Infection5 countries3420/3600 enrolled
$4.2B
Market Opportunity
NCT05712345Phase 3Immunology
ImmunoPharm Inc
IL-17 Inhibitor for Psoriatic Arthritis
IP-17XPsoriatic Arthritis4 countries756/900 enrolled
$3.8B
Market Opportunity
NCT05456789Phase 1/2Gene Therapy
GeneCure Therapeutics
AAV Gene Therapy for Hemophilia A
GC-HEMA-AHemophilia A3 countries12/24 enrolled
$2.5B
Market Opportunity
NCT05689012Phase 2Rare Disease
RareCure Pharma
Anti-FGF23 Antibody for Tumor-Induced Osteomalacia
RC-FGF23-01Tumor-Induced Osteomalacia5 countries28/48 enrolled
$650.0M
Market Opportunity
NCT05734567Phase 2Neuroscience
NeuroVax Biologics
Anti-amyloid-beta Vaccine for Early Alzheimer's Prevention
NV-ABETA-01Preclinical Alzheimer's Disease4 countries145/250 enrolled
$8.5B
Market Opportunity
NCT05545678Phase 2Metabolic
Metabolic Innovations
GLP-1/GIP Dual Agonist for Obesity
MI-GLP-GIP-01Obesity4 countries234/320 enrolled
$12.0B
Market Opportunity
NCT05612345Phase 2Oncology
OncoLink Therapeutics
HER2-Targeted ADC for Gastric Cancer
OL-HER2-ADCHER2+ Gastric Cancer5 countries78/110 enrolled
$1.8B
Market Opportunity
NCT05789012Phase 3Immunology
AutoImmune Solutions
FcRn Antagonist for Myasthenia Gravis
AIS-FCRN-01Generalized Myasthenia Gravis5 countries412/480 enrolled
$1.2B
Market Opportunity
Resources & References
ClinicalTrials.gov
US National Library of Medicine
Mayo Clinic
Medical Research & Education
NCBI
National Center for Biotechnology
Data sources and references for clinical trial information, medical research, and biotechnology research